Outcome of Long-Term Treatment with the 5α-Reductase Inhibitor Finasteride in Idiopathic Hirsutism: Clinical and Hormonal Effects During a 1-Year Course of Therapy and 1-Year Follow-Up

Naming a child after hair loss treatments like Propecia and Finasteride, with most users advising against it. The conversation includes humorous and critical responses, suggesting more conventional names.

User tried dermarolling for hair loss and shared progress pictures. Some suggest adding finasteride and minoxidil, while others debate effectiveness and frequency of dermarolling.

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.

Topical Finasteride doesn't directly reduce 5ar enzyme on scalp and has the same mechanism as oral, needing to go through the liver. Users debate the accuracy of this information and discuss various studies and experiences.